logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Bicalutamide CAS 90357-06-5

Bicalutamide CAS 90357-06-5

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 90357-06-5

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
90357-06-5
Appearance::
Off-white Crystalline Solid
Molecular Formula::
C18H14F4N2O4S
Molecular Weight::
430.37300
EINECS NO::
618-534-3
MDL NO::
MFCD00869971
CAS NO::
90357-06-5
Appearance::
Off-white Crystalline Solid
Molecular Formula::
C18H14F4N2O4S
Molecular Weight::
430.37300
EINECS NO::
618-534-3
MDL NO::
MFCD00869971
Bicalutamide CAS 90357-06-5

Product Description:

Product Name: Bicalutamide CAS NO: 90357-06-5

 

 

Synonyms:

N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide;

Cosudex;

BicalutaMide API;

 

 

Chemical & Physical Properties:

Appearance: Off-white crystalline solid

Assay :≥99.0%

Density: 1.52 g/cm3

Boiling Point: 650.3℃ at 760 mmHg

Melting Point: 191-193℃

Flash Point: 347.1℃

Refractive Index: 1.577

Storage Condition: Store in original container in a cool dark place.

 

 

Safety Information:

Hazard Class: 9

Safety Statements: S26; S36

HS Code: 2929909090

Packing Group: III

RIDADR: 3077

Risk Statements: R36/37/38

Hazard Code: Xi

 

 

Non-steroi-dal peripherally active antiandro-gen. Used as an antiandro-gen, antineoplastic (hormonal). Bicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. A non-steroi-dal, peripherally selective antiandro-gen, bicalutamide inhibits the action of dihydrotestostero-ne and testostero-ne at target sites by competitive binding to the cytosolic andro-gen receptor. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroi-d activity. The efficacy of bicalutamide as a monotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.